Last reviewed · How we verify
Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
Details
| Lead sponsor | University of Maryland, Baltimore |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 117 |
| Start date | 2002-05 |
| Completion | 2006-12 |
Conditions
- Schizophrenia
- Schizoaffective Disorder
Interventions
- galantamine
Primary outcomes
- Overall Cognitive Improvement Z-score — 12 weeks
Participants were administered an eight-test neuropsychological test battery at baseline and end-of-study. The battery included the following tests: working memory: WAIS-III Letter-Number Sequencing and Brief Assessment of Cognition in Schizophrenia Number Sequencing; verbal memory: California Verbal Learning Test (CVLT); visual memory: Brief Visuospatial Memory Test (BVMT); motor speed: Grooved Pegboard; processing speed: WAIS-III Digit Symbol and WAIS-III Symbol Search; and the Gordon Diagnostic System CPT. Alternate forms of the CVLT and BVMT were used for the two test occasions. For each neuropsychological test, participant scores were converted to z-scores: z = (score - baseline mean)/baseline SD. For the primary outcome measure, an overall composite z-score was computed from the average of the individual test z-scores. A positive z-score would reflect better performance compared to baseline; a negative z-score would reflect worse performance compared to baseline.
Countries
United States